Today, we announced the official launch of Nvelop Therapeutics, a company created to overcome the challenges of in vivo delivery for the next generation of genetic medicines. Read more: ow.ly/CBhs50Rbf0Q

We are pleased to introduce Nvelop’s Scientific Advisory Board, a distinguished group of leaders from the fields of gene therapy, gene editing, and drug delivery. Read more: ow.ly/G0vh50RuGvi

Today, at the American Society of Gene & Cell Therapy ASGCT annual conference, Nvelop Therapeutics will share the first preclinical data from our novel DLVR-M platform, created by gene editing pioneer Keith Joung, M.D., Ph.D. and his team at Mass General Hospital. See

On Friday, October 25th, Nvelop will deliver an oral presentation at the 31st Annual ESGCT Congress. Showcasing the latest preclinical data on DLVR-M, this presentation will further demonstrate the programmability and in vivo validation of our novel delivery platform. Read

Today, we celebrate a transformative milestone as the exceptional teams at Chroma Medicine and Nvelop Therapeutics unite to form nChroma Bio. Together, we are embarking on a shared mission to redefine the future of genetic medicines. Stay tuned for what’s next and be sure to follow us